Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Cash from Financing Activities (2024 - 2025)

Caris Life Sciences has reported Cash from Financing Activities over the past 2 years, most recently at $3.4 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $3.4 million for Q4 2025, up 1403.98% from a year ago — trailing twelve months through Dec 2025 was -$17.4 million (changed N/A YoY), and the annual figure for FY2025 was $665.0 million, up 232.01%.
  • Cash from Financing Activities for Q4 2025 was $3.4 million at Caris Life Sciences, up from -$21.1 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for CAI hit a ceiling of $3.4 million in Q4 2025 and a floor of -$21.1 million in Q3 2025.